|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001699,
umls-concept:C0003232,
umls-concept:C0007559,
umls-concept:C0032285,
umls-concept:C0036537,
umls-concept:C0040300,
umls-concept:C0205321,
umls-concept:C0220825,
umls-concept:C0242485,
umls-concept:C0521346,
umls-concept:C1517004,
umls-concept:C1707455
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1987-2-25
|
|
pubmed:abstractText |
The activity of ceftazidime was examined in a murine model of Klebsiella pneumoniae pneumonia in which the antibiotic was administered subcutaneously 6 h after intranasal infection and then twice daily for the next three days (i.e. seven doses). In a series of experiments using this test, the dose of ceftazidime giving 50% survival relative to controls (SD50) ranged from 1.0-9.0 mg/kg/dose while the dose required to reduce the log10 cfu/lung by 50% (CD50) ranged from 24-64 mg/kg/dose. Ceftazidime was considerably more effective than cefotiam, amoxycillin-clavulanic acid or kanamycin in the test. Pharmacokinetic studies with ceftazidime showed that no differences in respiratory tract penetration existed between uninfected mice and mice infected for 48 h with K. pneumoniae. The percentage penetration of ceftazidime from serum was 73% for pleural fluid, 44% for tracheal fluid, 27% for tracheal wall tissue and 17% for whole lung tissue after a subcutaneous injection of 100 mg/kg. At this dose, ceftazidime remained at supra-MIC concentrations for 2-3 h in all compartments examined.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0305-7453
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
599-608
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:3542926-Amoxicillin,
pubmed-meshheading:3542926-Animals,
pubmed-meshheading:3542926-Body Fluids,
pubmed-meshheading:3542926-Cefotaxime,
pubmed-meshheading:3542926-Cefotiam,
pubmed-meshheading:3542926-Ceftazidime,
pubmed-meshheading:3542926-Clavulanic Acid,
pubmed-meshheading:3542926-Clavulanic Acids,
pubmed-meshheading:3542926-Drug Combinations,
pubmed-meshheading:3542926-Female,
pubmed-meshheading:3542926-Kanamycin,
pubmed-meshheading:3542926-Klebsiella Infections,
pubmed-meshheading:3542926-Klebsiella pneumoniae,
pubmed-meshheading:3542926-Lung,
pubmed-meshheading:3542926-Mice,
pubmed-meshheading:3542926-Pleura,
pubmed-meshheading:3542926-Pneumonia,
pubmed-meshheading:3542926-Tissue Distribution,
pubmed-meshheading:3542926-Trachea
|
|
pubmed:year |
1986
|
|
pubmed:articleTitle |
Evaluation of ceftazidime in experimental Klebsiella pneumoniae pneumonia: comparison with other antibiotics and measurement of its penetration into respiratory tissues and secretions.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
